Caris Life Sciences

Caris Life Sciences is a leading, patient-centric, next-generation AI TechBio company and a pioneer in precision medicine. The company develops and commercializes innovative solutions aimed at transforming healthcare through the integration of comprehensive molecular data and scalable artificial intelligence (AI) and machine learning (ML) technologies. Its entire portfolio of precision medicine offerings is designed to benefit patients—initially with a focus on oncology—and serves clinical, academic, and biopharmaceutical markets.

Founded in 2008, Caris was established on the vision that combining a vast, consistently generated body of molecular information with robust data-driven insights could unlock the full potential of precision medicine. Over the past 17 years, the company has developed a comprehensive suite of proprietary molecular profiling solutions and built what it believes to be one of the most extensive multi-modal clinico-genomic datasets in oncology. This dataset is based on more than 6.5 million tests conducted across over 849,000 cases, generating over 38 billion molecular marker measurements.

Caris’ platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), AI/ML technologies, and high-performance computing. The strength of this differentiated platform has enabled the development of advanced diagnostic solutions that span the full continuum of cancer care—including early detection, minimal residual disease (MRD) tracking, therapy selection, and treatment monitoring. Additionally, the platform supports the creation of molecular signatures and the discovery and development of novel precision medicine therapeutics.

The company’s current commercial portfolio is focused on oncology and includes MI Profile, its tissue-based molecular profiling solution that has been the primary revenue driver, and Caris Assure, a novel, universal blood-based molecular profiling solution broadly launched in the first quarter of 2024 for therapy selection.